CCI-779 in metastatic melanoma: A phase II trial of the California cancer consortium

Cancer

Volumn 104, Issue 5, 2005, Pages 1045-1048

  Margolin, Kim ^a   Longmate, Jeffrey ^a   Baratta, Tracey ^a   Synold, Tim ^a   Christensen, Scott ^b   Weber, Jeffrey ^c   Gajewski, Thomas ^d   Quirt, Ian ^e   Doroshow, James H ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

CCI 779; Metastatic melanoma; Rapamycin analog

Indexed keywords

ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; DIPHENHYDRAMINE; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN DERIVATIVE; TEMSIROLIMUS;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DISEASE SEVERITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY CARCINOMA; MALE; MELANOMA; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SIROLIMUS;

EID: 23844476134     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21265     Document Type: Article

References (12)

1. Gara JF, Mellinghoff IK, Shi Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2004;279:2737-2746.
2. Hesbat M, Mellinghoff I, Tran C, et al. Enhanced sensitivity of PTEN-deflcient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA. 2001;98:10314-10319.
3. Schmezle T, Hall MN. TOR, a central controller of cell growth [review]. Cell. 2000;103:253-262.
4. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy [review]. Curr Opin Pharmacol. 2003;3:371-377.
5. Lu Y, Yu Q, Liu JH, et al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem. 2003;278:40057-40066.
6. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy [review]. Oncogene. 2000;19:6680-6686.
7. Raymond E, Alexandre J, Depenbrock H, et al. CCI-779, a rapamycin analog with antitumor activity: a phase I study utilizing a weekly schedule [abstract]. Proc Am Soc Clin Oncol. 2000;19:187a.
8. Peralba JM, DeGraffenried L, Friedrichs W, et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res. 2003;9:2887-2892.
9. Dutcher JP, Hudes G, Motzer R, et al. Preliminary report of a phase 1 study of intravenous (IV) CCI-779 given in combination with interferon-α (IFN) to patients with advanced renal cell carcinoma (RCC) [abstract]. Proc Am Soc Clin Oncol. 2003;22:213.
10. Chan S, Scheuten MF, Johnston S, et al. A phase 2 study of two dose levels of CCI-779 in locally advanced or metastatic breast cancer failing prior anthracycline and/or taxanc regimens [abstract]. Proc Am Soc Clin Oncol. 2003;22:193.
11. Atkins MB, Hidalgo M, Stadler W, et al. Ranomized phase 2 study of multiple close levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004; 22:909-918.
12. Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drag Resist Updates. 2001;4:378-391.